Literature DB >> 11321044

The p53 tumor suppressor: critical regulator of life & death in cancer.

D E Fisher1.   

Abstract

p53 is the most commonly mutated or deleted known gene in human cancer. The consequences of its disruption are profound, either in the germlines of patients with Li-Fraumeni Syndrome, or in mice with targeted gene knockouts. Abundant evidence suggests that p53 exerts regulation of cell cycle progression as well as apoptotic cell death, both in response to identical environmental or metabolic stressors. The specific decision of cell cycle arrest vs. death may underlie p53's differential ability to trigger death in cancer cells and arrest with repair in non-cancer cells, thus producing a therapeutic index pertinent to cancer therapy. Indeed, p53 status is likely to correlate with prognosis in many human cancers and in multiple animal tumor models. The mechanistic basis for p53's functions are still emerging, and will hopefully yield new therapeutic strategies applicable to treatment of the many poor-prognosis, p53-deficient human malignancies.

Entities:  

Mesh:

Year:  2001        PMID: 11321044     DOI: 10.1023/a:1009659708549

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  17 in total

1.  Expression profiling of p53-target genes in copper-mediated neuronal apoptosis.

Authors:  Jacob W Vanlandingham; Nadine M Tassabehji; Rikki C Somers; Cathy W Levenson
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 2.  Genetic influences on outcome following traumatic brain injury.

Authors:  Barry D Jordan
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

3.  Iberin induces cell cycle arrest and apoptosis in human neuroblastoma cells.

Authors:  Unmesh Jadhav; Ravesanker Ezhilarasan; Steven F Vaughn; Mark A Berhow; Sanjeeva Mohanam
Journal:  Int J Mol Med       Date:  2007-03       Impact factor: 4.101

4.  Drosophila p53 preserves genomic stability by regulating cell death.

Authors:  Naoko Sogame; Misoo Kim; John M Abrams
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

5.  Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury.

Authors:  Pascual Martínez-Lucas; Jerónimo Moreno-Cuesta; Dolores C García-Olmo; Francisco Sánchez-Sánchez; Julio Escribano-Martínez; Ana Cuartero del Pozo; Máxima Lizán-García; Damián García-Olmo
Journal:  Intensive Care Med       Date:  2005-07-09       Impact factor: 17.440

6.  A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug.

Authors:  Carmela Fimognari; Luca Sangiorgi; Silvia Capponcelli; Michael Nüsse; Silvia Fontanesi; Fausto Berti; Silvia Soddu; Giorgio Cantelli-Forti; Patrizia Hrelia
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

7.  Reversine induces caspase-dependent apoptosis of human osteosarcoma cells through extrinsic and intrinsic apoptotic signaling pathways.

Authors:  Jae-Sung Kim; In-A Cho; Kyeong-Rok Kang; HyangI Lim; Tae-Hyeon Kim; Sun-Kyoung Yu; Heung-Joong Kim; Seul Ah Lee; Sung Min Moon; Hong Sung Chun; Chun Sung Kim; Do Kyung Kim
Journal:  Genes Genomics       Date:  2019-04-05       Impact factor: 1.839

8.  Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation.

Authors:  Yan Liu; Csaba László; Yi Liu; Wei Liu; Xiaozhuo Chen; Susan C Evans; Shiyong Wu
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

9.  Pre-treatment with a non-therapeutic dose of cisplatin increases solid tumour response to liposomal-p53 gene therapy- An in vivo study.

Authors:  Jason C Steel; Wouter H J Kalle; Daniel J Dingwall; Heather M A Cavanagh; Mark A Burton
Journal:  Cancer Ther       Date:  2004

10.  OCT4B regulates p53 and p16 pathway genes to prevent apoptosis of breast cancer cells.

Authors:  Lu Meng; Hongyu Hu; Huifang Zhi; Yue Liu; Fangyu Shi; Laiguang Zhang; Yanjun Zhou; Aixing Lin
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.